0001724521-24-000062.txt : 20240228
0001724521-24-000062.hdr.sgml : 20240228
20240228195543
ACCESSION NUMBER: 0001724521-24-000062
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240226
FILED AS OF DATE: 20240228
DATE AS OF CHANGE: 20240228
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Jaen Juan C.
CENTRAL INDEX KEY: 0001422996
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38419
FILM NUMBER: 24698199
MAIL ADDRESS:
STREET 1: 850 MAUDE AVENUE
CITY: MOUNTAIN VIEW
STATE: CA
ZIP: 94043
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Arcus Biosciences, Inc.
CENTRAL INDEX KEY: 0001724521
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 473898435
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3928 POINT EDEN WAY
CITY: HAYWARD
STATE: CA
ZIP: 94545
BUSINESS PHONE: (510) 694-6200
MAIL ADDRESS:
STREET 1: 3928 POINT EDEN WAY
CITY: HAYWARD
STATE: CA
ZIP: 94545
4
1
wk-form4_1709168132.xml
FORM 4
X0508
4
2024-02-26
0
0001724521
Arcus Biosciences, Inc.
RCUS
0001422996
Jaen Juan C.
C/O ARCUS BIOSCIENCES, INC.
3928 POINT EDEN WAY
HAYWARD
CA
94545
0
1
0
0
President
1
Common Stock
2024-02-26
4
S
0
3900
20.06
D
1211365
I
By Trust
Common Stock
2024-02-27
4
S
0
23132
20.10
D
1188233
I
By Trust
Common Stock
341475
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 8, 2023.
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.01 to $20.13, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.29, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
/s/ Carolyn Tang, Attorney-in-Fact
2024-02-28